Other diseases
Wilson disease
肝豆状核变性(Wilson 病)
A rare inherited disease, passed on when both parents carry a changed ATP7B gene, in which copper builds up in the brain, liver, cornea and other organs, leading to progressive liver and nervous-system problems.
Definition adapted from MeSH (US National Library of Medicine)
Listed in China's first national rare-disease catalogue (2018, no. 37). National Health Commission 国卫医发〔2018〕10号
- hospitals in mainland China
- 28
- cities
- 17
with a paper from 2016–2025 or a registered study
where those hospitals are
Mainland China accounts for 34% of the world's English-language research papers on Wilson disease, 2021–2025 (16% in 2016–2020), and 19% of the world's registered trials on it have a site in China.
Research activity in public records, not a rating of care and not medical advice. How the numbers are made
28 hospitals in 17 cities
Order: papers led on Wilson disease, 2021–2025, then A–Z. Research activity, not a rating of care.
A hospital is listed when it led at least 2 papers or 1 trial on Wilson disease, or was a site in 2 or more trials. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first. Hospitals not listed may also treat it. Definitions
Cities with the most listed hospitals
Each opens Wilson disease in that city. 7 more cities are in the menu below.
- 52 papers ledNo open trial led
- 8 papers led
- 7 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers led
- 4 papers led
- 3 papers ledNo open trial led
- 3 papers led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 0 papers ledNo open trial led
No listed hospital matches these filters.
By university or health system 21
Hospitals carrying a university’s name, added together, plus papers that name only the university. Same order as above.
- 15 papers led6 hospitals
- 13 papers led4 hospitals
- 7 papers led1 hospital
- 7 papers led2 hospitals
- 7 papers led1 hospital
- 6 papers led4 hospitals
- 6 papers led1 hospital
- 4 papers led1 hospital
- 4 papers led3 hospitals
- 3 papers led2 hospitals
- 3 papers led4 hospitals
- 3 papers led1 hospital
- 2 papers led1 hospital
- 2 papers led1 hospital
- 2 papers led1 hospital
- 2 papers led1 hospital
- 2 papers led1 hospital
- 2 papers led1 hospital
- 1 paper led1 hospital
- 1 paper led1 hospital
- 1 paper led1 hospital
open trials on Wilson disease in China
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 8 Nov 2026, with at least one listed hospital as lead sponsor or site. 5 of them are led by a listed hospital. Check the registry for the current status. Whether someone can take part is decided by the study team.
Trials registered only in China’s own registry (ChiCTR) are not included. Questions to check before asking about a trial
What the phases mean (US National Cancer Institute)
- RecruitingTrientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.
- Phase
- Phase 3
- Started
- 2026-09
- Registry
- NCT07465718
Age 8 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Hangzhou
- RecruitingA Clinical Study on the Treatment of Wilson Disease With ATP7B mRNA/LNP (DSL101)
- Phase
- Early phase 1
- Started
- 2025-12
- Registry
- NCT07240896
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHefei
- RecruitingA Clinical Study to Evaluate the Safety and Efficacy of LY-M003 Injection in Patients With Wilson Disease
- Phase
- Early phase 1
- Started
- 2024-09
- Registry
- NCT06650319
Age 10 years to 60 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Registered Cohort Study on Wilson's Disease
- Phase
- Not given
- Started
- 2019-07
- Registry
- NCT04012658
Age not stated (registered criteria)
Led by First Affiliated Hospital of Fujian Medical UniversityFuzhou
- RecruitingChina Registry for Genetic / Metabolic Liver Diseases
- Phase
- Not given
- Started
- 2015-06
- Registry
- NCT03131427
Age not stated (registered criteria)
Led by Beijing Friendship Hospital; 1 listed hospital as study siteBeijing
- RecruitingRole for Biochemical Assays and Kayser-Fleischer Rings in Diagnosis of Wilson Disease
- Phase
- Not given
- Started
- 2004-01
- Registry
- NCT04965545
Age 6 years to 65 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingClinical Features and Outcome in Patients With Osseomuscular Type of Wilson's Disease
- Phase
- Not given
- Started
- 2004-01
- Registry
- NCT04965558
Age 6 years to 65 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingPhase I/II Clinical Study to Evaluate the Safety, Tolerability and Efficacy of LY-M003 Injection in Adult Patients With Wilson's Disease
- Phase
- Phase 1/Phase 2
- Started
- 2026-06
- Registry
- NCT07641140
Age 18 years to 60 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Before contacting a hospital
The same for every disease, so it is kept on one page. Each hospital page also has an enquiry letter in English and Chinese, and a name card to show staff.
- How to startTalk with the treating doctor, prepare the records hospitals ask for, then write to two or three hospitals.
- Questions to check before asking about a trialWhat the registered criteria usually ask about, and what to ask the study team.
- Common questionsInternational patients, costs, trials and visas.
National guideline (China)
- Rare disease diagnosis and treatment guideline (2019 edition), written for the first national rare-disease catalogueNational Health Commission 国卫办医函〔2019〕198号, 2019-02-27
Written for doctors, in Chinese. We link to the official notice only and do not summarise it; it is not medical advice.
Where these numbers come from
Papers
201 English-language PubMed papers on Wilson disease with an author in mainland China, 2021–2025; a hospital led a paper when its first or last author lists it first. Run the PubMed search
Trials
ClinicalTrials.gov records with a listed hospital as lead sponsor or site, as of 8 Nov 2026. ChiCTR is not included. Search ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.